에 대한 최신 뉴스 Cassava Sciences (NASDAQ:SAVA) 주식

Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

Short Ideas

Trading Ideas

$BTC

AMZN

MSTR

PLTR

RIVN

SAVA

TSLA

벤징가는 지난주 많은 투자자들이 선호하는 주식들의 전망을 조사한 결과를 바탕으로, 다음과  같이 주요 뉴스 몇 가지를 요약했다. 다우 지수가 1.4% 상승하여 11월 상승률을 7.5%로 끌어올린 반면, S&amp;P 500과 나스닥 종합지수는 각각 1.1% 상승하여 월간 상승률이 각각 5%와 6%를 넘어서며 다우와 S&amp;P 500의 2024년 최고의 월간 실적을 기록했다.

벤징가 불스 앤 베어스: 아마존, 테슬라, 리비안, 팔란티어 그리고 도지코인

News

Markets

월요일(25일) 미국 증시는  S&amp;P 500 지수와 다우존스 지수가 사상 최고치를 경신하며 역사적인 하루를 보냈다. 러셀 2000 지수 역시 글로벌 지정학적 긴장 완화, 대선 이후 강세 모멘텀, 계절적 호재에 힘입어 사상 최고치를 기록했다. 하지만 비트코인과 금은 하락세를 보였다.

월요일 주목받은 주식: 카사바 사이언스, 줌, 콜스, 리비안 및 테슬라

Biotech

Large Cap

Topics

Movers

General

AVXL

CHWY

SOFI

게임스탑(NYSE:GME), 소파이 테크놀로지스(NASDAQ:SOFI), 테슬라(NASDAQ:TSLA), 카사바 사이언스(NASDAQ:SAVA) 및 아나벡스 라이프 사이언스(NASDAQ:AVXL)는 금요일 스탁트위츠(Stocktwits)에서 가장 많이 언급된 상위 5개 종목이다. 무엇이 소매 투자자들의 주목을 받았는지 살펴보겠다.

금요일 상위 5개 트렌드 주식: 게임스탑, 소파이, 테슬라, 카사바 및 아나벡스에 대한 소식은?

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

SAVANNAH ENERGY PLC by Savannah Energy Plc

Savannah Energy PLC

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savara Inc

Savaria Corp

Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>), a leader in high-performance connectivity,&nbsp;today&nbsp;announced that it will display its innovative connectivity technology required for various AI applications at Embedded World 2025. Valens will display demonstrations in collaboration with a variety of companies, all offering the machine vision market cutting-edge solutions based on Valens' standard-compliant chipsets. These companies include Leopard Imaging, Acroname, Airy3D, Cherry Embedded Solutions, D3 Embedded, Fabrimex, Framos, Intel, RGo Robotics, and Teledyne e2v.

INTC

Valens Teams With Intel, Teledyne, and Others to Power Next-Gen Machine Vision Solutions, To Showcase AI-Driven Connectivity Tech at Embedded World 2025

VMAR

Vision Marine Technologies Announced The Filing Of A New Patent Application With Kennedy Lenart Spraggins, For Adaptive Control Of A Water Pump In A Marine Propulsion System

<ul>
<li>ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus</li>
<li>Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0</li>
<li>ESK-001 was generally well-tolerated at one year, with no new safety findings</li>
<li>Data further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis
<ul>
<li>Phase 3 ONWARD program ongoing with topline data expected in Q1 2026</li>
</ul>
</li>
</ul>

ALMS

Reported Saturday, Alumis' ESK-001 Demonstrates Sustained PASI 90 And PASI 100 Responses At Week 52 In Phase 2 Psoriasis Study

<ul>
<li>Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm</li>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2&nbsp;studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO</li>
<li>These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO</li>
</ul>

Reported Saturday, Johnson & Johnson's Icotrokinra Achieves Complete Skin Clearance In 46% Of Patients At Week 24, Showing Potential To Redefine Psoriasis Treatment

Economist Mohamed El-Erian highlighted the risks of an economic slowdown as Federal Reserve Chairman Jerome Powell reiterated that the economy was growing at a &#8220;solid pace&#8221; during his Friday address at the University of Chicago.
What Happened: During a podcast with Forward Guidance, the chief economic advisor at Allianz, El-Erian underscored &#8220;two disturbing data&#8221; sets on the stagflation side.
This included a fall in February&#8217;s ISM Manufacturing New Orders Index, which contracted to 48.6% after expanding for three months, indicating a weakening demand and a decline in new orders compared to the previous month.
The other data set highlighted by El-Erian included February&#8217;s job report, wherein nonfarm payrolls increased by 151,000 and the unemployment rate rose to 4.1%, the highest in 3.5 years, thus inducing uncertainty in the labour market. However, &#8220;one qualification is the slip in labor force participation,&#8221; from 62.6% to 62.4%, according to him.
&#8220;So the concern that we all have, is that while growth is slowing down, companies will feel that they need to pass on the higher costs into higher prices, of course that&#8217;s why tariffs play a major role because people are worried that it won&#8217;t be a once and for all effect, it may be a repeated effect, so there&#8217;s a price level and then there&#8217;s an inflation effect,&#8221; he said.
Economic slowdown was &#8220;the talk of the town,&#8221; El-Erian said while highlighting lower oil prices, negative stock futures, lower yields, and a weaker dollar on Monday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The possibility of lower US economic growth is now the talk of the town, amplified by this weekend's remarks from high-level officials. As you would expect, the market impact so far this early morning in Asian trading includes lower oil prices (with Brent again joining WTI below… <a href="https://t.co/egyftI2GpR">pic.twitter.com/egyftI2GpR</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1898950253325279263?ref_src=twsrc%5Etfw">March 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, President Donald Trump did not rule out a recession this year, acknowledging potential short-term turbulence from his economic agenda but expressing confidence in future prosperity. In a Fox News interview, he said, "I hate to predict things like that" and called the changes "very big."
See Also: <a href="https://www.benzinga.com/government/regulations/25/03/44160833/us-dollar-weakness-a-symptom-not-cause-argues-expert-as-economist-hails-devaluation-to-restore-global-growth">US Dollar Weakness A &#8216;Symptom Not Cause,&#8217; Argues Expert As Economist Hails Devaluation To &#8216;Restore Global Growth&#8217;</a>
Why It Matters: Despite the looming uncertainties and the difficulty of businesses to chart their way forward, Fed Chair Powell <a href="https://www.federalreserve.gov/newsevents/speech/powell20250307a.htm">said</a>, &#8220;The U.S. economy continues to be in a good place.&#8221;
He reaffirmed that the labor market is solid, and inflation has moved closer to the 2% longer-run goal. &#8220;At the Federal Reserve, we are intently focused on the dual-mandate goals given to us by Congress: maximum employment and stable prices,&#8221; Powell said.
Outlining the future course of action, he said that if inflation doesn&#8217;t fall to the 2% goal, the Fed will maintain policy restraint for longer and if the labor market weakens, the Fed will ease the policy accordingly.
Talking about the rate cuts, El-Erian added that he sees one cut and not three cuts in 2025 because of the persistent inflation and how the Fed is unlikely to &#8220;look through&#8221; that issue, the way they did in 2021.
Price Action: Futures of the Dow Jones slipped to 0.38%, whereas S&amp;P 500 and Nasdaq 100 declined by 0.49% and 0.61% respectively. Crude Oil WTI Futures dropped 0.51% to $66.7, the dollar index spot was down to the 103.816 level and the 10-year Treasury bonds yielded 4.29% as of 2:18 a.m., EDT.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, advanced on Friday. SPY gained 0.56% to $575.92, and QQQ was up 0.74% to $491.79, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44159401/rigetti-claims-leadership-in-quantum-computing-race-aims-to-scale-to-100-qubits-as-it-looks-to-catch-up-with-ibm-google">Rigetti Asserts &#8216;Leadership&#8217; In Quantum Computing Race, Aims To Scale To 100 Qubits As It Looks To Catch Up With IBM, Google</a></li>
</ul>
Photo courtesy: Federal Reserve

Government

Market Summary

Economics

Federal Reserve

US Economic Slowdown 'Talk Of The Town,' Says Economist Mohamed El-Erian As Fed Chair Powell Reaffirms Growth At 'Solid Pace'

<ul>
<li>Low disease activity was observed after a mean duration of 80 consecutive days off-treatment following success with VTAMA cream, with a mean weekly Peak Pruritus Numerical Rating Scale (PP-NRS) score of 2.9 at the end of the treatment-free interval</li>
<li>Data presented as late breaker at 2025 American Academy of Dermatology (AAD) Annual Meeting</li>
</ul>

Reported Saturday, Organon's VTAMA Phase 3 Data Shows 84% Of Patients Maintained Mild Disease After 80-Day Off-Treatment Interval In Adults And Children 2+

<ul>
<li>Significantly more patients treated with Sotyktu achieved ACR and PASI response rates and had greater improvements in patient-reported quality of life compared with placebo at Week 16</li>
<li>Sotyktu was well-tolerated in comparison with placebo and apremilast, demonstrating safety consistent with its established clinical profile</li>
</ul>

Reported Saturday, Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Showing Sotyktu Superior To Placebo In Psoriatic Arthritis

<ul>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO</li>
<li>Results pave the way to initiate the first-ever head-to-head study (ICONIC-ASCEND) seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe PsO</li>
</ul>

PTGX

Reported Saturday, Protagonist Reports Icotrokinra Achieved IGA 0/1 In 74% Of Patients At Week 24 With Favorable Safety Profile

Four Canadian stores of&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) have been suspected of exploiting the country&#8217;s EV rebate program. The stores are said to have sold an average of 30&nbsp;cars per hour over three days, claiming&nbsp;over 50% of the&nbsp;remaining rebate funds.
What Happened: Four Tesla stores in Canada managed to sell an average of 30 cars per hour, amounting to 120 cars per hour across all four locations, as <a href="https://www.thestar.com/news/canada/tesla-gamed-the-system-canadian-auto-dealers-stiffed-millions-when-u-s-giant-rushed-to/article_6d1025c6-fa0a-11ef-b780-a73277202cb2.html">reported </a>by the Toronto Star on Friday. 
This sales boom lasted for three consecutive days, even during hours when the stores were supposedly closed. Reportedly, a total of 8,653 cars were sold during the final 72 hours of the EV rebate program, also known as the iZEV Program.
Consequently, the Elon Musk-led company applied&nbsp;for C$43.1 million ($30 million) in&nbsp;rebates, which is over&nbsp;half of the remaining C$71.8&nbsp;million ($50 million) allocated for EV&nbsp;rebates.
The iZEV rebate program provided incentives ranging from C$2,500 ($1740.29) to C$5,000 ($3480.57) for purchasing electric vehicles and plug-in hybrids. Dealerships applied the rebate directly to the purchase price, anticipating reimbursement from the government.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
As a result of the incident, the rival brands haven&#8217;t been able to access the EV credits as Tesla claimed more than half of them. The Canadian Automobile Dealers Association (CADA), has received rebate claims for 2,295 electric vehicles from 226 dealers who are yet to receive the reimbursement, resulting in a collective shortfall of C$10 million.
CADA&#8217;s spokesperson, Huw Williams, told the Toronto Star, "Somehow, Tesla gamed the system. What we can't figure out is how this could have happened without setting off alarm bells."
Notably, Transport Canada, the body which oversees the iZEV rebate program, has not clarified whether any wrongdoing took place. It also stated that there is no restriction preventing Tesla from submitting rebate paperwork in bulk after delivering sold cars.
SEE ALSO: <a href="https://www.benzinga.com/news/25/03/44211240/warren-buffett-on-debt-and-donald-trumps-money-moves-trump-never-went-right">Warren Buffett on Debt and Donald Trump&#8217;s Money Moves: Trump &#8216;Never Went Right&#8217;</a>
Why It Matters: Tesla has been struggling in Canada, wherein thousands of Canadians have even signed a petition for revoking Musk&#8217;s Canadian citizenship. According to&nbsp;data from shop4tesla.com, the EV maker&#8217;s sales in Canada have dropped by approximately 70% between December 2024 and January 2025.
This surge in sales comes on the heels of Tesla&#8217;s recent offer of lifetime free supercharging for new Foundation Series Cybertruck purchases in Canada. Tesla <a href="https://www.benzinga.com/tech/25/03/44160193/tesla-offers-lifetime-free-supercharging-on-foundation-series-cybertruck-purchases-in-canada-mexico">announced this offer </a>to make the expensive truck more appealing to customers. The offer, valid for orders placed on or after March 5, lasts for the duration of the customer's ownership of the vehicle and is non-transferable.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44212993/palantir-ceo-alex-karp-meets-hyundai-vice-chair-to-enhance-ai-shipyard-defense-collaboration-amid-trumps-call-for-us-shipbuilding-revival">Palantir CEO Alex Karp Meets Hyundai Vice Chair to Enhance AI Shipyard, Defense Collaboration Amid Trump&#8217;s Call for US Shipbuilding Revival</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tesla Suspected Of EV Rebate Manipulation In Canada Amid Sudden Sales Surge Before Deadline: 'Tesla Gamed The System', Says Industry Body

<ul>
<li>Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) --</li>
<li>Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing --</li>
<li>In the Phase 2a clinical trial, bempikibart was observed to be safe and well-tolerated, with PK supporting subcutaneous dosing and receptor occupancy data demonstrating desired target engagement; clinical biomarkers showed changes in Th2 biomarkers, and expected on-mechanism changes in T-cells, indicative of potent IL-7 and TSLP inhibition --</li>
<li>Bempikibart development program remains on track with open-label extension study to initiate in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 --</li>
</ul>

QTTB

Reported Saturday, Q32 Bio Presents Phase 2a Data Showing Bempikibart Induces Sustained Hair Regrowth Post-Treatment In Severe Alopecia Areata

<ul>
<li>Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg</li>
<li>Patients treated with&nbsp;baricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo</li>
<li>Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need</li>
</ul>

INCY

Reported Saturday, Lilly And Incyte Present Late-Breaking Phase 3 Data Showing Baricitinib Significantly Improves Scalp, Eyebrow, And Eyelash Regrowth In Teens With AA

Macro Economic Events

Econ #s

Germany Trade Balance For January 16.0B Vs. 21.0B Est.; 20.7B Prior

Germany Industrial Production (MoM) For January 2.0% Vs. 1.6% Est.; -2.4% Prior

<ul>
<li>Tour 2025 Presented by Snapdragon, will see Manchester United return to the US for the third consecutive year, joining Premier League Summer Series for the first time</li>
<li>The round-robin series features three fixtures, with United set to face West Ham in New Jersey (26 July), AFC Bournemouth in Chicago (30 July) and Everton in Atlanta (3 August)</li>
</ul>

MANU

Reported Sunday, Manchester United To Play In Premier League Summer Series For First Time As Part Of Tour 2025 Presented By Snapdragon

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial&nbsp;to primarily enroll women using the two most widely used global TAVR devices

Reported Sunday, Medtronic Evolut TAVR Demonstrates Superior Durability And Valve Function In Small Annulus Patients, SMART Trial Shows

A subsidiary of Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XPNGF#OTC">XPNGF</a>), a Chinese electric vehicle maker and Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival, plans to become the world&#8217;s first mass producer of <a href="https://in.benzinga.com/insights/options/25/03/44111960/xpeng-options-trading-a-deep-dive-into-market-sentiment">flying cars by 2026</a>.
What Happened: Xpeng Aeroht&#8217;s &#8220;land aircraft carrier&#8221; — a modular vehicle featuring a passenger drone that unfolds from a six-wheeled van — completed its first public flight at the November Zhuhai Airshow and has reportedly secured approximately 3,000 intended orders, <a href="https://www.straitstimes.com/asia/mass-production-of-flying-cars-in-sight-amid-chinas-low-altitude-economy-push">reported</a> The Straits Times.
&#8220;In 2026, Xpeng plans to mass produce, for the first time, our modular flying car,&#8221; Xpeng Chairman and CEO He Xiaopeng said on Friday. The company broke ground in October on a factory designed to produce 10,000 flying cars annually when completed in the first quarter of 2026.
Priced at no more than 2 million yuan ($275,000), the vehicle accommodates four passengers in the car portion and two in the detachable drone. Initial applications will likely focus on tourism and short-haul rescue missions rather than everyday transportation.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/03/44212386/stock-futures-drop-as-reverse-trump-trade-takes-holdpeter-schiff-says-market-shift-long-overdue-and-will-likely-continue-for-a-decade" target="_blank" rel="noreferrer noopener">Stock Futures Drop As ‘Reverse Trump Trade' Takes Hold—Peter Schiff Says Market Shift ‘Long Overdue' And Will Likely Continue For A Decade</a>
Why It Matters: China&#8217;s government has prioritized the &#8220;low-altitude economy&#8221; — economic activity below 1,000 meters — labeling it a &#8220;new growth engine&#8221; in its 2024 annual work report. The sector, projected to reach one trillion yuan ($138 billion) by 2025, encompasses drone deliveries, <a href="https://www.benzinga.com/news/24/10/41551820/flying-taxis-are-almost-here-joby-archer-aviation-applaud-new-faa-regulations-for-evtol-aircraft">air shuttles, and flying taxis</a>.
Regulatory hurdles remain the primary challenge. He Xiaopeng cited concerns about vehicle certification, takeoff regulations, and pilot licensing requirements. &#8220;Right now, I see many problems,&#8221; he acknowledged.
Xpeng&#8217;s ADR stock on NYSE rose 6.16% to $23.60 in Friday&#8217;s trading, though analysts maintain an <a href="https://www.benzinga.com/quote/XPEV/analyst-ratings">average price target</a> of $17.44, suggesting a potential 37.04% downside ahead of the company&#8217;s fourth-quarter earnings report due Mar. 18.
<figure class="wp-block-image aligncenter size-full is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10020824/Screenshot-2025-03-10-at-11.35.56%E2%80%AFAM.png" alt="" class="wp-image-815913" style="width:694px;height:auto" /></figure>
Price Action: Xpeng traded at 88.85 HKD ($11.43) on the Hong Kong Exchange as of Monday at 1:21 PM local time, down 1.28% for the day.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44212672/jamie-dimon-cashed-out-234-million-in-jpmorgan-stock-warren-buffett-stockpiled-334-billion-in-cash-weeks-later-markets-crashed-coincidence" target="_blank" rel="noreferrer noopener">Jamie Dimon Cashed Out $234 Million In JPMorgan Stock, Warren Buffett Stockpiled $334 Billion In Cash — Weeks Later, Markets Crashed. Coincidence?</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Asia

XPEV

XPNGF

Tesla Rival XPeng Aims To Mass-Produce Flying Cars By 2026, But Regulators May Ground Takeoff

<ul>
<li>Authorized share increase approval supports the FX strategy and continued deliveries of the FF 91 2.0.</li>
<li>Company stock ticker to officially change to "FFAI" starting March 10, 2025.</li>
</ul>

FFIE

Reported Earlier, Faraday Future Gains Shareholder Backing To Raise Capital, Issue Shares For Operations, And Accelerate FX Project

MEOH

Reported Earlier, Methanex Geismar 3 Plant Outage To Impact Q2 Sales, Repair Costs Not Expected To Be Material

BTDR

Reported Earlier, Bitdeer Completes SEAL03 Chip Testing, Achieves 9.7J/TH Power Efficiency Ahead Of SEALMINER A3 Launch

<ul>
<li>Will add UNLOXCYT&#x2122; (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise</li>
<li>Will leverage Sun Pharma's global presence to accelerate patient access to UNLOXCYT&#x2122; (cosibelimab-ipdl)</li>
<li>Upfront cash payment of $4.10 per share of common stock, representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right for up to $0.70 per share on achievement of a milestone</li>
</ul>
&nbsp;

CKPT

Reported Earlier, Sun Pharma To Acquire Checkpoint Therapeutics In $355M Deal, Adding FDA-Approved UNLOXCYT For Advanced cSCC To Onco-Derm Portfolio

Legal

Press Releases

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

SAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Earnings

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

ALT5 Sigma

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Assertio Holdings

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

scPharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Third Harmonic Bio

Veru

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Rodman & Renshaw

B. Riley Securities

벤징가는 지난주 <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noopener" data-google-interstitial="false">많은 투자자들이 선호하는 주식들</a>의 전망을 조사한 결과를 바탕으로, 다음과  같이 주요 뉴스 몇 가지를 요약했다.
다우 지수가 1.4% 상승하여 11월 상승률을 7.5%로 끌어올린 반면, S&amp;P 500과 나스닥 종합지수는 각각 1.1% 상승하여 월간 상승률이 각각 5%와 6%를 넘어서며 다우와 S&amp;P 500의 2024년 최고의 월간 실적을 기록했다.
짧은 거래 주간에, 대통령 당선자 도널드 트럼프가 멕시코와 캐나다에서의 수입품에 25% 관세를, 중국 상품에 10% 인상을 발표하여 시장을 흔들었다. 이는 마약 밀매와 불법 이민 문제를 해결하려는 목적이다.
멕시코 페소와 캐나다 달러는 다년래 최저치로 급락한 후, 투자자들이 잠재적 영향을 재평가하면서 안정세를 보였다. 무역 전쟁에 대한 우려에도 불구하고, 넓은 주식 시장은 여전히 강세를 보였으며, 소형주가 포함된 iShares Russell 2000 ETF는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42250351/trumps-proposed-tariffs-target-mexico-canada-us-automakers-wall-street-shrugs-off-concerns-soars-to-record-highs-this-week-in-the-markets" target="_blank" rel="noopener" data-google-interstitial="false">역대 최고치</a>로 급등했다.
벤징가는 투자자들이 가장 선호하는 주식들에 대한 일일 보고서를 제공한다. 지난주 가장 긍정적(bullish)이고 부정적(bearish)인 포스트 몇 가지를 다시 살펴보겠다.
<h3 class="wp-block-heading">강세 뉴스</h3>
"<a href="https://kr.benzinga.com/news/usa/stocks/%EC%A7%90-%ED%81%AC%EB%A0%88%EC%9D%B4%EB%A8%B8-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%A3%BC%EA%B0%80-%EA%B8%89%EB%93%B1%EC%9D%80-%EC%9D%BC%EB%A1%A0-%EB%A8%B8%EC%8A%A4%ED%81%AC-%EB%95%8C%EB%AC%B8/" target="_blank" rel="noopener">일론 머스크가 팔란티어 주식 상승의 원인이라고 짐 크레이머가 주장</a>,"에서 Adam Eckert는 짐 크레이머가 팔란티어 테크놀로지스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/pltr" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for PLTR">PLTR</a>)의 올해 들어 275% 상승을 일론 머스크가 정부 효율부에 미치는 영향에 기인한다고 강조하며, 이는 팔란티어의 국방 관련 인공지능(AI) 사업을 강화할 것으로 예상된다.
"<a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%84%EB%A7%88%EC%A1%B4-ai-%EA%B0%9C%EB%B0%9C%EC%82%AC-%EC%95%A4%ED%8A%B8%EB%A1%9C%ED%94%BD%EC%97%90-80%EC%96%B5-%EB%8B%AC%EB%9F%AC-%ED%88%AC%EC%9E%90-%EC%84%9C%EB%A1%9C%EC%97%90%EA%B2%8C/" target="_blank" rel="noopener">아마존의 80억 달러 인공지능 개발사 앤트로픽 투자 &#8216;상호 이익&#8217;</a>,"에서 Erica Kollmann은 아마존닷컴(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/amzn" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for AMZN" data-google-interstitial="false">AMZN</a>)이 80억 달러 투자를 통해 앤트로픽(Anthropic)과의 AI 파트너십을 확장했다고 보도했다. BofA 증권의 한 분석가는 아마존의 맞춤형 트레이니엄(Trainium) 칩을 사용한 앤트로픽의 모델 교육을 위한 향상된 AWS 기능 및 비용 절감이 포함된 두 가지 모두에 대한 이점을 강조했다.
"<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42208108/surge-in-bitcoin-dogecoin-and-other-cryptos-boosting-home-ownership-among-low-income-americans-says-treasury-department" target="_blank" rel="noopener" data-google-interstitial="false">비트코인, 도지코인 등 암호화폐의 급증이 저소득층 주택 소유율을 높이고 있다고 재무부가 밝혔다</a>,"에서 Aniket Verma는 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD" data-google-interstitial="false">BTC</a>)과 도지코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/doge-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for DOGE/USD">DOGE</a>)의 이익이 저소득 가구의 주택 소유 증가와 연결되어 있으며 암호화폐에 집중적으로 투자한 지역의 주택 소유율이 2020년 4.1%에서 2024년 15.4%로 증가한 미국 재무부 보고서를 강조했다.
추가적인 긍정적인 뉴스는 다음과 같다:
<a href="https://kr.benzinga.com/news/usa/indices/%EB%8B%A8%EB%8F%85-%EB%9F%AC%EC%85%80-2000-%EC%A7%80%EC%88%98-%EC%82%AC%EC%83%81-%EC%B5%9C%EA%B3%A0%EC%B9%98-%ED%88%AC%EC%9E%90-%EC%A0%84%EB%9E%B5-%EC%A0%84%EB%AC%B8%EA%B0%80-sp-500/" target="_blank" rel="noopener">독점: 소형주가 최고가 기록, 전문가는 러셀 2000이 S&amp;P 500에 비해 &#8216;여전히 매우 할인되어 있다&#8217;고 주장</a>
<a href="https://kr.benzinga.com/news/korea/stocks/amd%EC%99%80-tsmc%EA%B0%80-%ED%95%A9%EC%9E%91%ED%95%98%EC%97%AC-%EC%8A%A4%EB%A7%88%ED%8A%B8%ED%8F%B0-%EC%8B%9C%EC%9E%A5%EC%97%90%EC%84%9C-%EC%82%BC%EC%84%B1%EC%A0%84%EC%9E%90%EC%97%90-%EB%8F%84/" target="_blank" rel="noopener">AMD, TSMC와 손잡고 스마트폰 시장에서 삼성전자와 경쟁</a>
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says" target="_blank" rel="noopener" data-google-interstitial="false">‘</a><a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%AD%EC%82%AC%EC%97%90-%EB%94%B0%EB%A5%B4%EB%A9%B4-%EC%A7%80%EA%B8%88%EC%9D%B4-%EC%A3%BC%EC%8B%9D-%EC%8B%9C%EC%9E%A5%EC%97%90%EA%B2%8C%EB%8A%94-%EC%98%AC%ED%95%B4-%EA%B0%80%EC%9E%A5-%EB%A9%8B/" target="_blank" rel="noopener">역사에 따르면, 지금이 주식 시장에게는 ‘올해 가장 멋진 시기'</a>
<h3>약세 뉴스</h3>
"<a href="https://www.benzinga.com/24/11/42181771/rivian-ceo-tesla-exec-slam-restrictions-on-direct-to-customer-sales" target="_blank" rel="noopener" data-google-interstitial="false">리비안 CEO, 테슬라 임원이 고객 직접 판매 제한에 반대: RJ 스카링는 &#8216;부패에 가장 가깝다&#8217;고 주장</a>,"에서 Anan Ashraf는 소비자 직접 판매를 금지하는 주법을 비판하는 리비안 오토모티브(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/rivn" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for RIVN">RIVN</a>)의 CEO RJ 스카링 및 테슬라(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tsla" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TSLA" data-google-interstitial="false">TSLA</a>)의 임원 센딜 팔라니(Sendil Palani)를 강조했다. 스카링은 시스템이 &#8220;부패에 가깝다&#8221;고 설명하면서 반경쟁적이며 딜러 지원 로비에 의해 주도된다고 말했다.
"<a href="https://www.benzinga.com/general/health-care/24/11/42168118/pharma-bro-martin-shkreli-tells-investors-to-short-sava-stock-falls-over-80-after-phase-3-update" target="_blank" rel="noopener" data-google-interstitial="false">‘마틴 쉬크렐리, 투자자들에게 &#8216;SAVA 공매도&#8217; 지시, 3단계 업데이트 후 주가 80% 이상 하락</a>,"에서 Chris Katje는 알츠하이머 치료제 시무필람(Simufilam)의 3상 결과가 1차 평가변수를 충족하지 못해 광범위한 투자자 실망으로 이어진 후 카사바 사이언스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/sava" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SAVA" data-google-interstitial="false">SAVA</a>) 주식이 80% 하락할 것이라는 마틴 슈크렐리(Martin Shkreli)의 정확한 예측을 자세히 설명했다.
"<a href="https://www.benzinga.com/news/small-cap/24/11/42170206/nano-nuclear-stock-plunges-after-60-million-private-placement-offering-details" target="_blank" rel="noopener" data-google-interstitial="false">나노 뉴클리어 주식이 6천만 달러의 사모펀딩 발표 후 급락</a>,"에서 Lekha Gupta는 나노 뉴클리어 에너지(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/nne" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for NNE" data-google-interstitial="false">NNE</a>)가 소형 원자로 발전과 전략적 성장 계획을 지원하기 위해 주당 24.00달러에 250만 주, 26.00달러에 워런트 250만 개가 포함된 6천만 달러 규모의 사모 투자를 통해 현금 보유액을 1억 2천만 달러 이상으로 늘린다는 발표 후 주가가 하락했다고 보도했다.
더 많은 부정적인 소식은 다음과 같다:
<a href="https://www.benzinga.com/news/global/24/11/42180906/larry-summers-warns-trump-policies-could-trigger-far-larger-stimulus-to-inflation-than-bidens-actions-as-sp-500-surges-markets-go-up-markets-go-down" target="_blank" rel="noopener" data-google-interstitial="false">래리 서머스는 트럼프 정책이 바이든의 행동보다 가격을 더 높일 수 있다고 경고: 시장은 인플레이션의 좋은 예측자가 아니다</a>
<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42180180/peter-schiff-warns-trumps-bitcoin-support-could-lead-to-economic-chaos-make-america-weaker-as-wall-street-misallocates-bigly" target="_blank" rel="noopener" data-google-interstitial="false">피터 쉬프는 트럼프의 비트코인 ​​지원이 경제적 혼란으로 이어질 수 있고 월가가 &#8216;크게&#8217; 잘못 할당함에 따라 미국을 &#8216;약하게&#8217; 만들 수 있다고 경고</a>
<a href="https://kr.benzinga.com/news/usa/economy/%EA%B3%A8%EB%93%9C%EB%A7%8C%EC%82%AD%EC%8A%A4-%EC%BA%90%EB%82%98%EB%8B%A4-%EB%8B%AC%EB%9F%AC%EB%A9%95%EC%8B%9C%EC%BD%94-%ED%8E%98%EC%86%8C-%EB%8C%80%EA%B7%9C%EB%AA%A8-%EB%A7%A4%EB%8F%84/" target="_blank" rel="noopener">골드만삭스는 캐나다 달러, 멕시코 페소의 대규모 매도를 예상하고 트럼프 관세가 USMCA 협정을 위협한다고 주장</a>
모든 최신 뉴스와 거래 아이디어를 확인하시려면 Benzinga를 Twitter에서 <a href="https://twitter.com/Benzinga">팔로우하세요</a>.
본 콘텐츠는 AI 도구의 도움을 받아 부분적으로 제작되었으며, 벤징가 편집자들의 검토 및 게재를 거쳤습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일(25일) 미국 증시는  S&amp;P 500 지수와 다우존스 지수가 사상 최고치를 경신하며 역사적인 하루를 보냈다. 러셀 2000 지수 역시 글로벌 지정학적 긴장 완화, 대선 이후 강세 모멘텀, 계절적 호재에 힘입어 사상 최고치를 기록했다. 하지만 비트코인과 금은 하락세를 보였다.
다우존스 지수는 1% 가까이 상승한 44,736.57포인트, S&amp;P 500 지수는 0.3% 상승한 5,987.37포인트, 나스닥 지수는 비슷한 비율로 상승하여 19,054.84포인트로 마감했다.
월요일에 개인 트레이더와 투자자들의 주목을 받은 상위 종목은 다음과 같다.
1. 카사바 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) 주가는 83% 이상 폭락하여 4.30달러로 마감했다. 이는 알츠하이머병 치료제를 위한 3상 시험 업데이트가 주요 목표를 달성하지 못한 결과에 따라 발생한 것이다. &#8216;파마 브로&#8217; 마틴 슈크렐리가 예측한 대로 1차 평가지표를 <a href="https://www.benzinga.com/general/health-care/24/11/42168118/pharma-bro-martin-shkreli-tells-investors-to-short-sava-stock-falls-over-80-after-phase-3-update">충족하지 못한</a> 결과가 발표되었다.
2. 줌 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) 주가는 3.67% 상승한 89.03달러에 마감했다. 줌은 <a href="https://www.benzinga.com/news/management/24/11/42176089/zoom-communications-q3-earnings-revenue-beat-eps-beat-online-churn-hits-all-time-low-company-name-change-and-more">3분기 매출이 11억 8천만 달러</a>로 예상치 11억 6천만 달러를 상회했다고 발표했다. 줌은 이제 9분기 연속 애널리스트 예상치를 상회했다.
 이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%A4%8C-%EC%BB%A4%EB%AE%A4%EB%8B%88%EC%BC%80%EC%9D%B4%EC%85%98%EC%8A%A4-3%EB%B6%84%EA%B8%B0-%EC%9D%B4%EC%9D%B5%EB%A7%A4%EC%B6%9C-%EC%98%88%EC%83%81%EC%9D%84-%EB%8A%A5%EA%B0%80-%EC%98%A8/">줌 커뮤니케이션스 3분기 이익·매출 예상을 능가, 온라인 이탈률 역대 최저, 회사명 변경 등</a>
3. 콜스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) 주가는 7.69% 상승한 18.34달러에 마감했다. 화요일 개장 전 3분기 실적을 발표할 예정이다. 매출 압박에도 불구하고 콜스는 운영 효율성 개선에 주력했으며, 2분기에는 총 마진이 39.6%로 59bp 상승했다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) 주가는 13.28% 상승한 11.60달러로 마감했다. 2020년 테슬라와의 소송에 대한 &#8220;조건부&#8221; 합의 보도에 대한 반응이었다. 테슬라는 합의 조건이 충족되면 12월 24일까지 사건 기각을 요청할 계획이다.
5. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) 주가는 3.96% 하락한 338.59달러에 마감되었다. 캘리포니아 주지사 개빈 뉴섬이 도널드 트럼프가 연방 $7,500의 전기차 세액공제를 폐지할 경우 구매자를 지원하는 새로운 제안을 발표했는데, 여기서 테슬라 전기차 모델은 제외되었다.
<a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하고 오늘의 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 생성되었고, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), 소파이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), 카사바 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) 및 아나벡스 라이프 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>)는 금요일 스탁트위츠(Stocktwits)에서 가장 많이 언급된 상위 5개 종목이다. 무엇이 <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">소매 투자자들의 주목을 받았는지</a> 살펴보겠다.
GME GM-밈: 게임스탑이 이번 주 1위를 차지했다. 이 주식은 기본적 요인이 전혀 없는 상황에서 거래량이 폭발적으로 증가하면서 움직였다. 원조 밈 주식인 만큼 이런 경향은 자주 발생한다. 키스 길(Keith Gill), 일명 로어링 키티(Roaring Kitty)가 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) 주식을 <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours" target="_blank" rel="noopener" data-google-interstitial="false">10월 말</a>에 매도한 이후 게임스탑 주식은 꾸준히 상승하고 있다.
소파이 급등: 소파이의 주식은 투자자들이 두 번째 트럼프 대통령 하의 규제 완화를 기대하는 가운데 <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41847971/jim-cramer-this-tech-stock-is-a-buy-sofi-technologies-is-good" target="_blank" rel="noopener" data-google-interstitial="false">이번 주</a>에 17% 상승했다. 이 주식이 강한 거래량으로 상승하며 이 날 9% 이상 상승했다.
다음 읽기: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">트럼프 대통령 당선이 EV 대기업 테슬라와 빅 3 자동차 제조사에 미치는 의미는?</a>
테슬라와 대통령: 테슬라의 주식은 도널드 트럼프가 대통령 선거에서 승리한 후 급등했다. 테슬라의 CEO인 일론 머스크는 여러 차례 캠페인에서 트럼프와 함께했으며, 행정부의 직책에 임명될 가능성도 있다.
투자자들은 또한 트럼프의 전기차(EV) 및 관세 정책이 테슬라에 유리하다고 생각할 수 있다. 두 가지 모두 미국 기반 EV 대기업에 대한 경쟁을 줄일 수 있기 때문이다. 이 주식은 화요일 이후로 30% 상승했으며, 시가총액은 <a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion">1조 달러</a>를 넘어섰다.
SAVA: 카사바 사이언스는 스탁트위츠에서 자주 언급되는 종목이다. HC 웨인라이트(HC Wainwright &amp; Co.)의 애널리스트 버논 베르나디노(Vernon Bernardino)가 카사바 사이언스를 매수 등급으로 재확인하고 목표 주가를 116달러로 유지했다. 현재 주가는 27달러 미만이다.
AVXL: 아나벡스 라이프 사이언스는 또 다른 큰 거래량을 보인 바이오텍 주식으로, 뉴스가 없었음에도 불구하고 큰 변동이 있었다. 벤징가 프로의 데이터에 따르면, 주식의 21.78%가 공매도되고 있으며, 금요일 거래량은 평균 거래량의 세 배 이상이었다.
GME, SOFI, TSLA, SAVA, AVXL 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>의 데이터에 따르면, 게임스탑 주식이 6.1% 상승하여 24.88달러로 마감하였고, 소파이 주식이 9.33% 상승하여 13.01달러로 마감하였으며, 테슬라 주식이 8.19% 상승하여 321.22달러로 마감하였고, 카사바 사이언스 주식이 6.55% 상승하여 27.00달러로 마감하였으며, 아나벡스 라이프 사이언스 주식이 21% 상승하여 9.24달러로 마감했다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">트럼프의 잠재적 &#8216;보건 차관&#8217; 로버트 F. 케네디 주니어가 백신 주식을 흔든다: &#8216;선제적 반응&#8217;</a></li>
</ul>
Image: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일 카사바 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>)의 주가는 <a href="https://www.benzinga.com/general/biotech/24/07/39891005/cassava-sciences-advances-alzheimers-drug-through-high-stakes-phase-3-trials" target="_blank" rel="noopener" data-google-interstitial="false">알츠하이머 치료제 시무필람</a>(simufilam)에 관한 주요 발표 이후 주가가 급등했다.
어떤 일이 (What Happened): 이 주식은 당일 정규 거래에서 26.47% 상승한 22.22달러에 마감했다. 이후 시간외 거래에서 0.99% 하락했다.
카사바는 오픈 라벨 연장 시험을 최대 36개월 더 연장할 계획을 발표했다. 이 연장은 이전에 무작위 시험에 참여한 환자들이 진행 중인 3상 시험 결과를 기다리는 동안 계속해서 치료를 받을 수 있도록 한다다.
회사의 이러한 결정은 환자들이 블라인드 시험을 완료한 후에도 치료를 지속할 수 있도록 도와주기 위한 것이다. 또한, 카사바는 이러한 연장 시험에서 인지 기능과 혈장 바이오마커 모니터링을 포함하여 시무필람의 장기적인 효능과 안전성에 대한 더 많은 데이터를 수집할 계획이다.
기타 사항: 카사바 사이언스의 리더십은 이번 조치의 중요성을 강조했다. 이사회 의장인 릭 베리(Rick Barry)는 회사에게 큰 헌신이긴 하지만 시험을 연장하는 것이 환자들에게 최선의 선택이라고 말했다. 최고 의료 책임자인 제임스 쿠피엑(James Kupiec)도 이 확장이 임상 연구 사이트의 요청에 대한 응답이며, 회사의 환자 중심 접근 방식과 일치한다고 언급했다.
이 회사는 현재 두 가지 중요한 3상 연구인 RETHINK-ALZ와 REFOCUS-ALZ를 진행하고 있다. RETHINK-ALZ는 804명의 환자를 대상으로 하는 52주 시험으로, 2024년 말에 결과가 나올 예정이다. REFOCUS-ALZ는 1,125명의 환자를 대상으로 하는 76주 시험으로, 2025년 중반에 주요 결과가 발표될 것으로 예상된다. 이 연구들은 미국, 캐나다, 푸에르토리코, 호주 및 한국의 여러 사이트에서 진행되고 있다.
카사바 사이언스는 또한 8월 13일에 2분기 실적을 발표할 예정이며, Benzinga Pro에 따르면 주당 40센트의 손실이 예상된다.
<figure class="wp-block-image size-large is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-468615" style="width: 500px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31143237/SAVA-1-1024x547.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31143237/SAVA-1-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31143237/SAVA-1-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31143237/SAVA-1-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31143237/SAVA-1.png 1383w" alt="" width="1024" height="547" /></a></figure>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Cassava Sciences

뉴스

에 대한 최신 뉴스 Cassava Sciences (NASDAQ:SAVA) 주식

일요일, 12월 01, 2024

화요일, 11월 26, 2024

토요일, 11월 09, 2024

목요일, 8월 01, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌